Peptides have moved rapidly from biomedical research into mainstream fitness culture, marketed as a targeted means of enhancing muscle growth, recovery and overall physiological function. They are often presented as a “precision” alternative to traditional performance-enhancing approaches, promising specific, controllable effects with fewer risks. However, a closer examination of the scientific literature reveals a more complex and far less certain picture. While peptide biology is well understood at a mechanistic level, the evidence supporting meaningful improvements in training adaptation and athletic performance is limited, inconsistent and frequently constrained by methodological weaknesses. The key issue is therefore not whether peptides can influence physiology, but whether they meaningfully improve adaptation to training, which remains the primary determinant of performance outcomes.
What Are Peptides
Peptides are short chains of amino acids that function predominantly as signalling molecules within the body. Unlike larger proteins, which primarily serve structural or enzymatic roles, peptides regulate biological processes by binding to receptors and initiating intracellular responses. A number of critical physiological regulators are peptides, including insulin and insulin-like growth factor‑1, which plays a central role in skeletal muscle growth, regeneration and adaptation through its influence on satellite cell activity and protein synthesis pathways (Ahmad et al., 2020). In applied fitness settings, peptides typically refer to synthetic analogues designed to manipulate these signalling systems, often through hormonal or regenerative pathways.
Mechanisms of Action
The Growth Hormone–IGF‑1 Axis
The most extensively discussed mechanism underpinning peptide use in fitness is the growth hormone–IGF‑1 axis. Growth hormone is secreted from the pituitary gland and stimulates the production of IGF‑1 both systemically and within muscle tissue. IGF‑1 then binds to receptors on muscle cells, activating intracellular pathways such as PI3K/Akt and mTOR, which regulate protein synthesis, cell proliferation and survival (Machida and Booth, 2004; Ahmad et al., 2020). Through these mechanisms, IGF‑1 facilitates satellite cell activation, muscle fibre hypertrophy and tissue repair following damage.
Interaction With Exercise Physiology
Resistance exercise itself strongly activates the same pathways targeted by peptides. Mechanical loading increases local IGF‑1 expression within muscle tissue and stimulates mTOR signalling, which is central to muscle protein synthesis (Machida and Booth, 2004). This highlights an important limitation: peptides are not introducing new biological mechanisms but attempting to manipulate systems already maximally stimulated through appropriate training and nutrition.
Tissue Repair and Regeneration Pathways
Some peptides are proposed to influence recovery through mechanisms such as angiogenesis, enhanced collagen synthesis, modulation of inflammatory pathways and improved fibroblast activity. These mechanisms underpin claims relating to improved healing of connective tissues and reduced injury recovery time. However, the evidence supporting these claims is heavily dominated by preclinical animal research, with limited high-quality human validation.
Training Adaptation: The Central Issue
Training adaptation is a multifactorial process driven by the interaction between mechanical, metabolic and biological signals. It depends on progressive overload, motor unit recruitment, neuromuscular adaptation, nutrient availability and recovery processes rather than a single signalling pathway. Peptides influence only a narrow component of this system, primarily intracellular signalling.
Adaptation follows a sequence whereby a sufficient training stimulus produces intracellular signalling, leading to protein synthesis, structural change and ultimately functional improvement. Peptides act at the signalling stage but do not replace the initial mechanical stimulus. This leads to a critical principle: increasing signalling alone does not produce meaningful adaptation in the absence of appropriate training.
A consistent finding across the literature is the discrepancy between molecular responses and functional outcomes. Studies often demonstrate increases in IGF‑1, activation of anabolic signalling pathways and changes in gene expression, yet these do not consistently translate into increased strength, improved power output or enhanced performance. For example, collagen peptide studies show increased signalling pathway activation without significant improvements in strength or functional performance (Centner et al., 2022; Balshaw et al., 2022). This highlights that molecular changes are necessary but not sufficient for meaningful adaptation.
Adaptation is also constrained by limiting factors such as training stimulus, protein intake, energy availability and recovery. Peptides do not override these constraints, meaning increased signalling cannot compensate for inadequate training or nutrition. Additionally, most peptide studies are conducted in untrained or clinical populations, where adaptive capacity is higher. In trained athletes, physiological systems are already optimised, meaning the marginal benefit of additional signalling is likely to be minimal due to ceiling effects.
Evidence Base
Growth Hormone and Related Interventions
The strongest human evidence comes from research on growth hormone. Randomised controlled trials demonstrate that growth hormone administration can increase lean body mass and reduce fat mass, particularly in ageing or hormone-deficient populations (Hoffman et al., 2004; Fernández‑Garza et al., 2025). However, interpretation of these findings is complex. Growth hormone increases extracellular fluid retention and connective tissue mass, meaning increases in lean mass do not necessarily represent increases in contractile muscle tissue.
Despite changes in body composition, functional outcomes are inconsistent. Upper-body strength often shows no significant improvement, while lower-body strength gains are modest and variable (Tavares et al., 2013). Performance outcomes are rarely improved, indicating that growth hormone-related hypertrophy is not equivalent to training-induced hypertrophy.
Growth hormone interventions are also associated with metabolic consequences, including reduced insulin sensitivity and impaired glucose tolerance (Fernández‑Garza et al., 2025). These findings raise concerns regarding long-term health risks and highlight the importance of risk–benefit analysis.
Collagen Peptides and Resistance Training
Research on collagen peptides provides additional insight into the disconnect between molecular signalling and functional outcomes. Acute studies demonstrate increased activation of anabolic signalling pathways following collagen supplementation and resistance exercise (Centner et al., 2022). However, longer-term studies show increases in muscle volume without corresponding improvements in strength or performance (Balshaw et al., 2022). This suggests that structural changes at the tissue level do not necessarily translate into functional improvements.
Protein Versus Peptides
Comparative studies consistently demonstrate that protein quality and quantity are more important determinants of adaptation than peptide supplementation. Whey protein has been shown to produce greater increases in muscle size than collagen peptides, despite matched leucine content, while strength gains remain similar (Jacinto et al., 2022). This reinforces established principles of sports nutrition, where total protein intake and amino acid availability drive adaptation.
Recovery Peptides
Recovery peptides such as BPC‑157 are widely discussed within fitness circles but lack robust human evidence. Systematic reviews indicate that the majority of studies are preclinical, with very few human trials and a lack of randomised controlled evidence (Vasireddi et al., 2025). Narrative reviews further confirm that although animal models demonstrate promising effects, these findings have not been reliably replicated in humans (McGuire et al., 2025). Current claims regarding recovery peptides are therefore not supported by strong clinical data.
Study Design Limitations
The peptide evidence base is limited by consistent methodological issues. Many studies involve small sample sizes, reducing statistical power and increasing variability. Research is often conducted in non-athletic populations, limiting applicability to trained individuals. Study durations are typically short, preventing long-term conclusions about adaptation or safety.
There is a heavy reliance on surrogate outcomes such as lean body mass, hormone concentrations and gene expression, which do not necessarily reflect real-world performance outcomes. Confounding variables such as training programme design, nutritional intake and recovery practices are often not well controlled. Additionally, there is a lack of replication across independent studies and a significant translational gap between animal and human research, particularly in recovery peptide investigations.
Safety Considerations
Acute risks include fluid retention, impaired glucose metabolism, reduced insulin sensitivity and injection-related complications. Chronic risks are less well understood but potentially more serious. IGF‑1 promotes cell proliferation and inhibits apoptosis, and chronic elevation is associated with increased cancer risk (Ahmad et al., 2020). Long-term concerns also include cardiovascular strain, endocrine disruption and metabolic dysfunction. A key limitation is the absence of long-term human safety data, meaning the true risk profile remains unclear.
Practical Implications
Peptides should not be considered first-line interventions for performance enhancement. Training, nutrition and recovery remain the primary drivers of adaptation. Peptides should be viewed as experimental due to the limited and inconsistent evidence base. The risk–reward profile is currently unfavourable, with modest potential benefits and uncertain long-term risks.
Practitioners should prioritise evidence-based strategies and educate athletes on the limitations of current knowledge. Any consideration of peptide use should occur within a medically supervised context. Focus should remain on progressive resistance training, adequate protein intake, creatine supplementation and sleep optimisation, all of which are supported by high-quality evidence.
Final Conclusion
Peptides are biologically plausible and mechanistically sound, influencing key pathways involved in muscle growth and recovery. However, the current evidence indicates that they do not meaningfully enhance training adaptation or performance beyond what can be achieved through well-structured training and nutrition.
The literature is constrained by methodological weaknesses, non-athletic populations, reliance on surrogate outcomes and limited long-term data. At the same time, safety concerns remain unresolved.
From a performance perspective, peptides do not replace training, do not reliably enhance adaptation and should currently be regarded as experimental rather than evidence-based tools. The fundamentals of performance continue to provide the most effective and reliable outcomes.
References
Ahmad, S.S. et al. (2020) Implications of insulin-like growth factor‑1 in skeletal muscle and various diseases. Cells, 9(8), 1773
Balshaw, T.G. et al. (2022) The effect of specific bioactive collagen peptides on function and muscle remodeling during human resistance training. Acta Physiologica
Centner, C. et al. (2022) Supplementation of specific collagen peptides following high-load resistance exercise upregulates gene expression. Frontiers in Physiology
Fernández‑Garza, L.E. et al. (2025) Growth hormone and aging: a clinical review. Frontiers in Aging
Hoffman, A.R. et al. (2004) Growth hormone replacement therapy in adult-onset GH deficiency. Journal of Clinical Endocrinology & Metabolism
Jacinto, J.L. et al. (2022) Whey protein supplementation is superior to leucine-matched collagen peptides. International Journal of Sport Nutrition and Exercise Metabolism
Machida, S. and Booth, F.W. (2004) Insulin-like growth factor‑1 and satellite cell proliferation. Proceedings of the Nutrition Society
McGuire, F.P. et al. (2025) Regeneration or risk? A narrative review of BPC‑157. Current Reviews in Musculoskeletal Medicine
Tavares, A.B. et al. (2013) Effects of growth hormone administration on muscle strength. International Journal of Endocrinology
Vasireddi, S. et al. (2025) Systematic review of BPC‑157 for orthopaedic applications. American Journal of Sports Medicine
Leave a Reply